bioAffinity Technologies Achieves Japanese Patent for CyPath® Lung
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a pioneering biotechnology firm, has made a significant advancement in the field of early-stage lung cancer detection. The company proudly announces the receipt of a Japanese patent for its innovative method in predicting lung cancer risks through the CyPath® Lung diagnostic test.
Understanding CyPath® Lung
The CyPath® Lung test represents a breakthrough in noninvasive diagnostics. Utilizing advanced flow cytometry and artificial intelligence, this test analyzes patient sputum to accurately identify cell populations that indicate lung malignancies. This method is crucial for early detection, allowing for more effective treatment options to be considered when the likelihood of successful intervention is highest.
Details of the Japanese Patent
Titled “System and Method for Determining the State of Health of the Lungs,” the newly awarded Japanese patent marks an essential milestone in bioAffinity Technologies’ ongoing commitment to enhancing its patent portfolio, which encompasses 17 granted U.S. and international patents along with 30 additional applications currently under review.
Significance of the Patent
This patent is particularly noteworthy as it represents the first standalone patent for the CyPath® Lung test, recognizing its distinct medical application. Maria Zannes, President and CEO of bioAffinity Technologies, emphasized the importance of this development, stating it as a vital step in safeguarding their intellectual property. She expressed optimism about future patents in other regions, which will further solidify their market position.
The Impact on Lung Cancer Detection
Lung cancer remains one of the most lethal forms of cancer across the globe. The potential for CyPath® Lung to revolutionize early diagnosis is immense, as early detection significantly improves survival rates. As research continues, bioAffinity Technology aims to contribute positively to the health outcomes of patients at risk for lung cancer.
Research and Development Initiatives
bioAffinity Technologies is not resting on its laurels with the patent acquisition. The firm is actively undertaking research and development initiatives that will not only enrich their current methodologies but also pave the way for new market opportunities. The scientific team's dedication to developing effective diagnostics underscores their aim to be at the forefront of cancer detection technologies.
About bioAffinity Technologies, Inc.
Founded with a mission to tackle the pressing need for noninvasive diagnostic solutions for early-stage cancers and other lung diseases, bioAffinity Technologies is committed to innovation. The company’s flagship product, CyPath® Lung, is tailored to deliver exceptional sensitivity, specificity, and accuracy in lung cancer detection, advocating for better health protocols.
Future Directions and Patents
The recent Japanese patent is just the beginning. bioAffinity Technologies plans to expand its footprint in the global market, promoting its groundbreaking diagnostics. These efforts will hinge on not only the existing intellectual property but also the ongoing developments in their research pipeline.
Frequently Asked Questions
What is CyPath® Lung?
CyPath® Lung is a noninvasive diagnostic test developed by bioAffinity Technologies to detect early-stage lung cancer through the analysis of patient sputum.
Why is the Japanese patent significant?
The Japanese patent affirms the innovation behind CyPath® Lung as a unique diagnostic tool, protecting the company's intellectual property in an important market.
How does CyPath® Lung function?
The test utilizes flow cytometry and AI technology to identify specific cell populations in sputum that may indicate the presence of lung cancer.
What are the accuracy rates of CyPath® Lung?
Clinical studies have shown that CyPath® Lung has a sensitivity of 92%, specificity of 87%, and 88% accuracy in detecting lung cancer in high-risk patients.
How is bioAffinity Technologies planning to grow?
The company is focused on expanding its patent portfolio and pursuing research initiatives that will lead to more advancements in cancer diagnostics and treatment.
